Dexin Ding
Papers
2
Total Citations
17
H-Index
2
About
Dexin Ding is a pioneering urologic surgeon and researcher at the forefront of robotic surgery innovation, with a focused expertise in minimally invasive treatments for renal and prostate cancers. His most significant contributions lie in the rigorous clinical evaluation of emerging Chinese robotic surgical systems—specifically the KangDuo-SR-2000 and EDGE MP1000—against the established global gold standard, the Da Vinci Xi. In a landmark prospective, non-randomized clinical trial (2025, 12 citations), Ding demonstrated comparable perioperative safety and efficacy for these domestic platforms in robot-assisted partial nephrectomy and radical prostatectomy. He further validated these findings in a dedicated study on early renal cancer (2025, 5 citations), analyzing 170 patients to confirm that the Chinese systems achieve equivalent outcomes in tumor resection and renal function preservation. This work is instrumental in reducing healthcare costs and advancing surgical autonomy, positioning Ding as a key figure in the global democratization of robotic surgery. His research directly informs clinical adoption and device regulation, making him a vital voice in the transition toward accessible, high-tech surgical care.
Research Focus
Key Achievements
Top Papers
- 1
- 2